Pathophysiology and therapeutic targets

Johns Hopkins Advanced Studies in Medicine

Volumn 10, Issue 1, 2010, Pages 9-13

  Moss, Richard B ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DENUFOSOL; DORNASE ALFA; IBUPROFEN; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BIOFILM; CONFERENCE PAPER; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENE TARGETING; GENOTYPE; HAEMOPHILUS INFECTION; HUMAN; INFECTION; INFLAMMATION; ION TRANSPORT; LIFE EXPECTANCY; LUNG FUNCTION; LUNG INFECTION; MUCOCILIARY CLEARANCE; MUCUS SECRETION; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTION; SODIUM TRANSPORT; STAPHYLOCOCCUS INFECTION;

EID: 77953378283     PISSN: None     EISSN: 15303004     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229-1256.
2. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J. 2004;23:146-158.
3. Konstan MW. Dornase alfa and progression of lung disease in cystic fibrosis. Pediatr Pulmonol. 2008;43:S24-S28.
4. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157-170.
5. Banner KH, De Jonge H, Elborn S, et al. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. J Cyst Fibros. 2009;8:1-8.
6. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-969.
7. Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med. 2005;172:1246-1252.
8. Ramsey BW. Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. Proc Am Thorac Soc. 2007;4:359-363.
9. Worlitzsch D, Tarran R, Ulrich M. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109:317-325.
10. 10.Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-1756.
11. Starner T, McCray P. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med. 2005;143:816-822.
12. Nichols DP, Konstan MW, Chmiel JF. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol. 2008;35:135-153.